Skip to main navigation
Skip to search
Skip to main content
Oregon Health & Science University Home
Help & FAQ
Home
Profiles
Research units
Core Facilities
Publications
Search by expertise, name or affiliation
Translation of the Philadelphia chromosome into therapy for CML
Brian J. Druker
Knight Cancer Institute
Research output
:
Contribution to journal
›
Article
›
peer-review
594
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Translation of the Philadelphia chromosome into therapy for CML'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Philadelphia Chromosome
85%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
70%
Imatinib Mesylate
60%
Hematologic Neoplasms
13%
Neoplasms
12%
Chromosome Aberrations
12%
Protein-Tyrosine Kinases
12%
Therapeutics
10%
History
10%
Clinical Trials
8%
Survival
7%
Chemical Compounds
Imatinib
100%
Resistance
21%
Tyrosine
15%